Key result
Adjunctive corticosteroids show ~100% clinical improvement in EV-D68 and mycobacterial coinfection.
Why the study?
Very few studies have described the clinical aspects of coinfection with Enterovirus D68 and mycobacteria.
Case Report (n=3)
No
Enterovirus D68 coinfection can severely exacerbate pulmonary inflammation in adults with active mycobacterial disease, and short-term systemic corticosteroids alongside anti-mycobacterial therapy may facilitate clinical recovery.
Answers are grounded in this paper and cite their sources.
May support short-term corticosteroids in EV-D68/mycobacterial coinfection; hypothesis-generating pending controlled trials.
The threat of viral epidemics to long-standing diseases, such as mycobacterial infection, is constantly evolving. Enterovirus D68 (EV-D68) is an emerging cause of respiratory infection and has raised great interest since its first outbreak in 2014. Very few studies have been done to describe the clinical aspects of the coinfection of EV-D68 and mycobacteria, so this study was conducted to help round out the understanding of this coinfection pattern. We observed three adult cases of EV-D68 and mycobacteria, who were admitted to the first affiliated hospital of Zhejiang University in August/September 2024. Only one case had a definite past history of immunodeficient disease and received long-term corticosteroid treatment, and the other two were previously healthy. The diagnoses of EV-D68 and mycobacterial infection were all simultaneously confirmed through the metagenomic Next—Generation Sequencing in bronchoalveolar lavage fluid specimens. All three patients were presented with severe respiratory symptoms, such as fever, cough, dyspnea and tachypnea, without any manifestations of central nervous system involvement. The radiological findings in chest CT scans varied from patchy opacity to massive consolidation. The individualized anti-mycobacterium treatment showed little therapeutic effect, while the improvement of symptoms and pulmonary lesions in chest CT was observed after starting or intensifying the administration of corticosteroid. All patients had a marked clinical improvement when discharged from hospital, and it took about 6–9 months for the lung lesions of mycobacterial infections to nearly resolve. These cases illustrate the potential for EV-D68 coinfection to exacerbate pulmonary inflammation in patients with mycobacterial disease, highlighting the need for vigilance regarding possible viral coinfections in settings with a high tuberculosis burden, such as China.
No takes yet. Share an insight, caveat, or question.
Bao et al. (2026) conducted a case report in Enterovirus D68 (EV-D68) and mycobacterial coinfection (n=3). Corticosteroid therapy (methylprednisolone) added to individualized anti-mycobacterial treatment was evaluated on Clinical improvement of respiratory symptoms and resolution of pulmonary lesions on chest CT. Corticosteroid initiation or intensification alongside anti-mycobacterial therapy led to marked clinical and radiological improvement in all 3 adult patients with EV-D68 and mycobacterial coinfection.
Synapse has enriched 10 related papers. Consider them for comparative context: